CA-MAWI-DNA-TECHNOLOGIES
25.1.2021 15:02:12 CET | Business Wire | Press release
Mawi DNA Technologies’ iSWAB-Microbiome-EL sample collection technology enables BioTech Africa to implement and launch a new ultra-high throughput COVID-19 testing program. This breakthrough, in conjunction with the ProbeSure™ COVID-19 One Step RT-PCR Kit from 3CR Bioscience, is designed to scale up to a capacity of 200,000 tests per day.
“We are extremely proud and humbled to be part of South Africa’s fight against COVID-19 through BioTech Africa’s mass testing efforts,” said Dr. Bassam El-Fahmawi, President and CTO, Mawi DNA Technologies.
In addition, Dr. Jenny Leslie, COO of BioTech Africa, worked closely with Scilutions Labware and Hook Diagnostics to identify the best products and supplier partners who could provide reagents to streamline the testing workflow, but also scale to the projected numbers with minimal supply chain disruption.
“For the sample collection step, Mawi DNA Technologies’ iSWAB-Microbiome-EL (‘Extractionless’) product was chosen for its multiple benefits. This includes enabling direct PCR by removing the RNA extraction step along with extended room temperature stabilization of viral RNA. iSWAB technology also enables simple and efficient non-invasive self-collection, a key component of BioTech Africa’s testing strategy to encourage widespread compliance,” said Dr. Leslie. She added, “When used in tandem with the 3CR Bioscience ProbeSure™ kit, we can provide high throughput testing and faster sample-to-result turnaround time, while significantly reducing reagents, plastics and testing workflow footprint.”
“iSWAB room temperature sample collection and stabilization technology has been well validated in the field with millions of samples tested thus far,” said Dr. Bassam El-Fahmawi. He added that Mawi DNA was pleased to work with Scilutions Labware and Hook Diagnostics to deploy its products on a global scale to help alleviate the socioeconomic impact that COVID-19 brought on the world.
Hook Diagnostics CEO Simon Kratzat added, “Our mission at Hook Diagnostics is to enable affordable population scale testing. We are honored to make this a reality for BioTech Africa together with Mawi DNA, 3CR and Scilutions.”
About Mawi DNA Technologies
Mawi DNA Technologies has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Its flagship product iSWAB-DNA has gained significant market traction due to its ability to be used for animals and all human population segments from infants to the elderly, with robust DNA yield and low bacterial DNA content. iSWAB-Microbiome has gained worldwide acceptance as a superior collection technology for COVID-19 samples. Mawi DNA has expanded its offerings to include collection technologies for intact cells and whole blood. For more information, visit http://www.mawidna.com .
About BioTech Africa
BioTech Africa specializes in recombinant protein production and bioprocessing. Driven by the global requirement for improved in vitro diagnostics, its current range of highly purified recombinant proteins are used in the manufacture of diagnostic test kits for point of care rapid diagnostics and research institutions. BioTech Africa offers a variety of protein expression platforms along with a host of other protein services, including protein refolding and structural biology analysis. For more information, visit http://www.biotechafrica.com .
About Scilutions Labware
Scilutions is an innovative manufacturer of scientific products. Through collaboration with the academic, industrial and scientific communities, its manufacturing capabilities are aligned to ensure that the company is optimized to support critical biomedical operations. For more information, visit http://www.scilutionslabware.com .
About 3CR Bioscience
3CR Bioscience is a world-leading manufacturer of innovative PCR-based reagents. Primary products, PACE™ and ProbeSure™, are used in hundreds of institutions worldwide, from small academic labs to large multinational companies. 3CR has developed the ProbeSure™ COVID-19 One Step RT-PCR Kit which combines high sensitivity and specificity with low cost and has been designed for use in real-time or high-throughput endpoint processes. For more information visit https://3crbio.com/ .
About Hook Diagnostics
Hook Diagnostics is committed to making worldwide population-scale testing faster and more affordable using only the most high quality and cutting edge tools available. For more information, visit http://www.hookdx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005262/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
Interactive Brokers Offers Eligible Clients Access to the Anthropic, PBC Initial Public Offering13.11.2026 11:00:00 CET | Press release
ADVERTISEMENT This advertisement constitutes an advertisement within the meaning of the Prospectus Regulation and marketing communication within the meaning of MiFID II and is prepared by and in the sole responsibility of Interactive Brokers Ireland Limited, North Dock One, 91/92 North Wall Quay, Dublin 1, D01 H7V7, Ireland, a firm authorized and regulated by the Central Bank of Ireland. Eligible clients of Interactive Brokers Ireland Limited can participate in the offering. Interactive Brokers Ireland Limited, part of Interactive Brokers Group (Nasdaq: IBKR), an automated global broker, today announced that eligible clients can participate in the initial public offering (the “Offering”) of Anthropic, PBC (the “Company”). Through the IBKR platform, eligible clients resident and located in Denmark, Finland, France, Germany, Ireland, the Netherlands, Norway, Spain, and Sweden can review the Offering and submit an application during the offer period, which is open for all eligible clients
Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release
Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom